Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction

ABSTRACT

A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising
         determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with
           (a) kidney function in a subject or   (b) kidney dysfunction in said subject or   (c) enhanced risk of adverse events or   (d) success of a therapy or intervention in a diseased subject.

Subject matter of the present invention is a method for (a) diagnosingor monitoring kidney function in subject or (b) diagnosing kidneydysfunction in a subject or (c) predicting or monitoring the risk of anadverse events in a diseased subject wherein said adverse event isselected from the group comprising worsening of kidney dysfunctionincluding kidney failure, loss of kidney function and end-stage kidneydisease or death due to kidney dysfunction including kidney failure,loss of kidney function and end-stage kidney disease or (d) predictingor monitoring the success of a therapy or intervention comprising

-   -   determining the level of Pro-Enkephalin (PENK) or fragments        thereof of at least 5 amino acids in a bodily fluid obtained        from said subject; and        -   (a) correlating said level of Pro-Enkephalin or fragments            thereof with kidney function in a subject or        -   (b) correlating said level of Pro-Enkephalin or fragments            thereof with kidney dysfunction wherein an elevated level            above a certain threshold is predictive or diagnostic for            kidney dysfunction in said subject or        -   (c) correlating said level of Pro-Enkephalin or fragments            thereof with said risk of an adverse event in a diseased            subject, wherein an elevated level above a certain threshold            is predictive for an enhanced risk of said adverse events or        -   (d) correlating said level of Pro-Enkephalin or fragments            thereof with success of a therapy or intervention in a            diseased subject, wherein a level below a certain threshold            is predictive for a success of therapy or intervention.

Met-Enkephalin, a 5 amino acid peptide derived from the Enkephalinprecursor (Pre-Pro-Enkephalin), also named “Opioid Growth Factor” (OGF)is released together with Pro-Enkephalin-fragments. The mature peptidebinds to different opioid receptors (Koneru et al., 2009). Enkephalin(OGF) was found to have a number of physiological functions. In the CNSit down regulates Substance P associated pain signalling, it plays rolesas cytokine (Plotnikoff et al, 1997). Pro-Enkephalin related peptidesexhibiting antibiotic actions (Goumon et al., 1998). Pro-Enkephalin andEnkephalin exhibits anti tumor action and acting as pro-apoptotic agents(Tavish et al., 2007, Donahue et al., 2011, Zagon et al., 2009).Enkephalin was reported to be elevated in kidney dysfunction (Smith etal, 1985, Zoccali et al., 1987, Smith et al., 1981). Enkephalin isproduced as the larger Pro-Enkephalin and converted by proteolysis tothe mature pentapeptides. During maturation process a number ofPro-Enkephalin fragments are generated, which are co-released togetherwith Enkephalin (Ernst et al., 2006).

Subject matter of the present invention is the use of Pro-Enkephalin(PENK) or fragments thereof as marker for kidney function anddysfunction and its clinical utility in healthy and diseased subjects.Subject matter of the present invention is a method for diagnosing ormonitoring kidney function in subject or diagnosing kidney dysfunctionin a subject or predicting the risk of death or adverse events in adiseased subject.

A subject of the present invention was also the provision of theprognostic and diagnostic power of PENK or fragments thereof for thediagnosis of kidney function, dysfunction and the prognostic value indiseased subjects.

Surprisingly, it has been shown that PENK or fragments are powerful andhighly significant biomarker for kidney, its function, dysfunction, riskof death or adverse events and prognosis and monitoring success oftherapy or intervention.

Subject matter of the present invention is method for (a) diagnosing ormonitoring kidney function in subject or (b) diagnosing kidneydysfunction in a subject or (c) predicting or monitoring the risk of anadverse events in a diseased subject wherein said adverse event isselected from the group comprising worsening of kidney dysfunctionincluding kidney failure, loss of kidney function and end-stage kidneydisease or death due to kidney dysfunction including kidney failure,loss of kidney function and end-stage kidney disease or (d) predictingor monitoring the success of a therapy or intervention comprising

-   -   determining the level of Pro-Enkephalin (PENK) or fragments        thereof of at least 5 amino acids in a bodily fluid obtained        from said subject; and        -   (a) correlating said level of Pro-Enkephalin or fragments            thereof with kidney function in a subject or        -   (b) correlating said level of Pro-Enkephalin or fragments            thereof with kidney dysfunction wherein an elevated level            above a certain threshold is predictive or diagnostic for            kidney dysfunction in said subject or        -   (c) correlating said level of Pro-Enkephalin or fragments            thereof with said risk of an adverse event in a diseased            subject, wherein an elevated level above a certain threshold            is predictive for an enhanced risk of said adverse events or        -   (d) correlating said level of Pro-Enkephalin or fragments            thereof with success of a therapy or intervention in a            diseased subject, wherein a level below a certain threshold            is predictive for a success of therapy or intervention.

According to the present invention said Pro-Enkephalin or fragmentsthereof is not leu-enkephalin and not met-enkephalin in one specificembodiment. In another specific embodiment said Pro-Enkephalin fragmentis MR-Pro-Enkephalin (MRPENK) or a fragment thereof having at least 5amino acids.

To put it in other words: Subject matter of the present invention ismethod for (a) diagnosing or monitoring kidney function in subject or(b) diagnosing kidney dysfunction in a subject or (c) predicting ormonitoring the risk of an adverse events in a diseased subject whereinsaid adverse event is selected from the group comprising worsening ofkidney dysfunction including kidney failure, loss of kidney function andend-stage kidney disease or death due to kidney dysfunction includingkidney failure, loss of kidney function and end-stage kidney disease or(d) predicting or monitoring the success of a therapy or interventioncomprising

-   -   determining the level of immunoreactive analyte by using at        least one binder that binds to a region within the amino acid        sequence of Pro-Enkephalin (PENK) in a bodily fluid obtained        from said subject; and        -   (a) correlating said level of immunoreactive analyte with            kidney function in a subject or        -   (b) correlating said level of immunoreactive analyte with            kidney dysfunction wherein an elevated level above a certain            threshold is predictive or diagnostic for kidney dysfunction            in said subject or        -   (c) correlating said level of immunoreactive analyte with            said risk of an adverse event in a diseased subject, wherein            an elevated level above a certain threshold is predictive            for an enhanced risk of said adverse events or        -   (d) correlating said level of immunoreactive analyte with            success of a therapy or intervention in a diseased subject,            wherein a level below a certain threshold is predictive for            a success of therapy or intervention.

According to the present invention said immunoreactive analyte is notleu-enkephalin and not met-enkephalin in a specific embodiment. Inanother specific embodiment said immunoreactive analyte isMR-Pro-Enkephalin (MRPENK) or a fragment thereof having at least 5 aminoacids.

This means in case a binder is used in the methods of the presentinvention that binds to a region within the amino acid sequence ofPro-Enkephalin (PENK) in a bodily fluid then the terms “determining thelevel of Pro-Enkephalin (PENK) or fragments thereof of at least 5 aminoacids in a bodily fluid obtained from said subject” are equivalent to“determining the level of immunoreactive analyte by using at least onebinder that binds to a region within the amino acid sequence ofPro-Enkephalin (PENK) in a bodily fluid obtained from said subject”. Ina specific embodiment a binder is used in the methods of the presentinvention that binds to a region within the amino acid sequence ofPro-Enkephalin (PENK) in a bodily fluid. In a specific embodiment saidbinder used in the methods of the present invention does not bind to aregion within the amino acid sequence of leu-enkephalin ormet-enkephalin in a bodily fluid. In another specific embodiment of thepresent invention said at least one binder binds to MR-Pro-Enkephalin(MRPENK) or a fragment thereof having at least 5 amino acids.

The term “subject” as used herein refers to a living human or non-humanorganism. Preferably herein the subject is a human subject. The subjectmay be healthy or diseased if not stated otherwise. In one embodiment ofthe invention said subject has not suffered a stroke. In anotherembodiment said subject is not an acute stroke patient.

The term “elevated level” means a level above a certain threshold level.The term “elevated” level may mean a level above a value that isregarded as being a reference level.

Predicting or monitoring the success of a therapy or intervention may bee.g. the prediction or monitoring of success of renal replacementtherapy using measurement of Pro-Enkephalin (PENK) or fragments thereofof at least 5 amino acids.

Predicting or monitoring the success of a therapy or intervention may bee.g. the prediction or monitoring of success of treatment withhyaluronic acid in patients having received renal replacement therapyusing measurement of Pro-Enkephalin (PENK) or fragments thereof of atleast 5 amino acids.

Predicting or monitoring the success of a therapy or intervention may bee.g. the prediction or monitoring recovery of renal function in patientswith impaired renal function prior to and after renal replacementtherapy and/or pharmaceutical interventions using measurement of PENK orfragments thereof of at least 5 amino acids.

A bodily fluid may be selected from the group comprising blood, serum,plasma, urine, cerebro spinal liquid (csf), and saliva.

Determination of Pro-Enkephalin or fragments thereof exhibit kidneyfunction in a subject. An increased concentration of Pro-Enkephalin orfragments thereof indicates a reduced kidney function. During follow upmeasurements, a relative change of Pro-Enkephalin or fragments thereofcorrelates with the improvement (lowering Pro-Enkephalin or fragmentsthereof) and with the worsening (increased Pro-Enkephalin or fragmentsthereof) of the subjects kidney function.

Pro-Enkephalin or fragments thereof are diagnostic for kidneydysfunction wherein an elevated level above a certain threshold ispredictive or diagnostic for kidney dysfunction in said subject. Duringfollow up measurements, a relative change of Pro-Enkephalin or fragmentsthereof correlates with the improvement (lowering Pro-Enkephalin orfragments thereof) and with the worsening (increased Pro-Enkephalin orfragments thereof) of the subjects kidney dysfunction.

Pro-Enkephalin or fragments thereof are superior in comparison to othermarkers for kidney function/dysfunction diagnosis and follow up (NGAL,blood creatinine, creatinine clearance, Cystatin C, Urea). Superioritymeans higher specificity, higher sensitivity and better correlation toclinical endpoints.

Correlating said level of Pro-Enkephalin or fragments thereof with arisk of death or an adverse event in a diseased subject, wherein anelevated level above a certain threshold is predictive for an enhancedrisk of death or adverse events. Also in this aspect, Pro-Enkephalin orfragments thereof are superior to above mentioned clinical markers.

Risk according to the present invention correlates with the risk asdefined by the RIFLE criteria, Venkatamaran and Kellum, 2006).

The diseased person may suffer from a disease selected from chronicalkidney failure caused by immune responses to inflammation, acute kidneyfailure caused by decreased blood flow which may occur with extremelylow blood pressure caused by trauma, traumatic patients, surgery,stroke, acute and chronic renal failure, patients with SIRS, Sepsis,Septic Shock, Stroke, acute- and post Myocardial Infarction, acute- andchronic Heart Failure, local and systemic bacterial and viralinfections, autoimmune diseases, burned patients, cancer, liverdiseases, lung diseases, patients receiving nephrotoxins such ascyclosporine, antibiotics including aminoglycosides and anticancer drugssuch as cisplatin.

The therapy or intervention supporting or replacing kidney function maycomprise various methods of renal replacement therapy including but notlimited to hemodialysis, peritoneal dialysis, hemofiltration and renaltransplantation.

An adverse event may be selected from the group comprising worsening ofkidney dysfunction including kidney failure, loss of kidney function andend-stage kidney disease (according to the RIFLE criteria, Venkatamaranand Kellum, 2006).

In one embodiment of the invention it should be understood that the termfragments of Pro-Enkephalin also include Leu-Enkephalin andMet-Enkephalin.

Subject matter according to the present invention is a method whereinthe level of Pro-Enkephalin or fragments thereof of at least 5 aminoacids is determined by using a binder, at least one binder, toPro-Enkephalin or fragments thereof of at least 5 amino acids. In oneembodiment of the invention said binder is selected from the groupcomprising an antibody, an antibody fragment or a non-Ig-Scaffoldbinding to Pro-Enkephalin or fragments thereof of at least 5 aminoacids. In a specific embodiment said at least one binder binds to aregion with the sequences selected from the group comprising SEQ ID No.1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In a specific embodiment said binderdo not bind to enkephalin peptides [Met]enkephalin SEQ ID No:3, and[Leu]enkephalin. SEQ ID No:4. In a specific embodiment said at least onebinder binds to a region with the sequences selected from the groupcomprising SEQ ID No. 1, 2, 5, 6, 7, 8, 9 and 10. In another specificembodiment said at least one binder binds to a region with the sequencesselected from the group comprising SEQ ID No. 2, 5, 6, and 10. Inanother very specific embodiment said binder bind to Pro-Enkephalin119-159, Mid regional Pro-Enkephalin-fragment, MRPENK.

Pro-Enkephalin has the following sequence:

(Pro-Enkephalin (1-243) SEQ ID NO. 1ECSQDCATCSYRLVRPADINFLACVMECEGKLPSLKIWETCKELLQLSKPELPQDGTSTLRENSKPEESHLLAKRYGGFMKRYGGFMKKMDELYPMEPEEEANGSEILAKRYGGFMKKDAEEDDSLANSSDLLKELLETGDNRERSHHQDGSDNEEEVSKRYGGFMRGLKRSPQLEDEAKELQKRYGGFMRRVGRPEWWMDYQKRYGGFLKRFAEALPSDEEGESYSKEVPEMEKRYGGF MRF

Fragments of Pro-Enkephalin that may be determined in a bodily fluid maybe e.g. selected from the group of the following fragments:

SEQ ID NO. 2 (Synenkephalin, Pro-Enkephalin 1-73)ECSQDCATCSYRLVRPADINFLACVMECEGKLPSLKIWETCKELLQLSK PELPQDGTSTLRENSKPEESHLLA SEQ ID NO. 3 (Met-Enkephalin) YGGFMSEQ ID NO. 4 (Leu-Enkephalin) YGGFL SEQ ID NO. 5 (Pro-Enkephalin 90-109)MDELYPMEPEEEANGSEILA SEQ ID NO 6: (Pro-Enkephalin 119-159, Midregional Pro-Enkephalin-fragment, MRPENK)DAEEDDSLANSSDLLKELLETGDNRERSHHQDGSDNEEEVSSEQ ID NO. 7 (Met-Enkephalin-Arg-Gly-Leu) YGGFMRGLSEQ ID NO. 8 (Pro-Enkephalin 172-183) SPQLEDEAKELQSEQ ID NO. 9 (Pro-Enkephalin 193-203) VGRPEWWMDYQSEQ ID NO. 10 (Pro-Enkephalin 213-234) FAEALPSDEEGESYSKEVPEMESEQ ID NO. 11 (Pro-Enkephalin 213-241) FAEALPSDEEGESYSKEVPEMEKRYGGF MSEQ ID NO. 12 (Met-Enkephalin-Arg-Phe) YGGFMRF

Determining the level of Pro-Enkephalin including Leu-Enkephalin andMet-Enkephalin or fragments thereof may mean that the immunoreactivitytowards Pro-Enkephalin or fragments thereof including Leu-Enkephalin andMet-Enkephalin is determined. A binder used for determination ofPro-Enkephalin including Leu-Enkephalin and Met-Enkephalin or fragmentsthereof depending of the region of binding may bind to more than one ofthe above displayed molecules. This is clear to a person skilled in theart.

Thus, according to the present invention the level of immunoreactiveanalyte by using at least one binder that binds to a region within theamino acid sequence of any of the above peptide and peptide fragments,(i.e. Pro-Enkephalin (PENK) and fragments according to any of thesequences 1 to 12), is determined in a bodily fluid obtained from saidsubject; and correlated to the specific embodiments of clinicalrelevance.

In a more specific embodiment of the method according to the presentinvention the level of MRPENK is determined (SEQ ID NO. 6:Pro-Enkephalin 119-159, Mid regional Pro-Enkephalin-fragment, MRPENK).In a more specific embodiment the level of immunoreactive analyte byusing at least one binder that binds to MR-PENK is determined and iscorrelated to the above mentioned embodiments according to the inventionto the specific embodiments of clinical relevance, e.g.

-   -   correlating said level of immunoreactive analyte with kidney        function in a subject or        -   (b) correlating said level of immunoreactive analyte with            kidney dysfunction wherein an elevated level above a certain            threshold is predictive or diagnostic for kidney dysfunction            in said subject or        -   (c) correlating said level of immunoreactive analyte with            said risk of an adverse event in a diseased subject, wherein            an elevated level above a certain threshold is predictive            for an enhanced risk of said adverse events or        -   (d) correlating said level of immunoreactive analyte with            success of a therapy or intervention in a diseased subject,            wherein a level below a certain threshold is predictive for            a success of therapy or intervention.

Alternatively the level of any of the above analytes may be determinedby other analytical methods e.g. mass spectroscopy.

Thus, subject matter of the present invention is method for (a)diagnosing or monitoring kidney function in subject or (b) diagnosingkidney dysfunction in a subject or (c) predicting or monitoring the riskof an adverse events in a diseased subject wherein said adverse event isselected from the group comprising worsening of kidney dysfunctionincluding kidney failure, loss of kidney function and end-stage kidneydisease or death due to kidney dysfunction including kidney failure,loss of kidney function and end-stage kidney disease or (d) predictingor monitoring the success of a therapy or intervention comprising

-   -   determining the level of immunoreactive analyte by using at        least one binder that binds to a region within the amino acid        sequence of a peptide selected from the group comprising the        peptides and fragments of SEQ ID No. 1 to 12 in a bodily fluid        obtained from said subject; and        -   (a) correlating said level of Pro-Enkephalin or fragments            thereof with kidney function in a subject or        -   (b) correlating said level of Pro-Enkephalin or fragments            thereof with kidney dysfunction wherein an elevated level            above a certain threshold is predictive or diagnostic for            kidney dysfunction in said subject or        -   (c) correlating said level of Pro-Enkephalin or fragments            thereof with said risk of an adverse event in a diseased            subject, wherein an elevated level above a certain threshold            is predictive for an enhanced risk of said adverse events or        -   (d) correlating said level of Pro-Enkephalin or fragments            thereof with success of a therapy or intervention in a            diseased subject, wherein a level below a certain threshold            is predictive for a success of therapy or intervention.

In a specific embodiment the level of immunoreactive analyte isdetermined by using at least one binder that binds to a region withinthe amino acid sequence of a peptide selected from the group comprisingPro-Enkephalin or fragments thereof of at least 5 amino acids. In aspecific embodiment said at least one binder binds to a region with thesequences selected from the group comprising SEQ ID No. 1, 2, 3, 4, 5,6, 7, 8, 9 and 10. In a specific embodiment said binder do not bind toenkephalin peptides [Met]enkephalin SEQ ID No:3, and [Leu]enkephalin.SEQ ID No:4. In a specific embodiment said at least one binder binds toa region with the sequences selected from the group comprising SEQ IDNo. 1, 2, 5, 6, 7, 8, 9 and 10. In another specific embodiment said atleast one binder binds to a region with the sequences selected from thegroup comprising SEQ ID No. 2, 5, 6, and 10. In another very specificembodiment said binder binds to Pro-Enkephalin 119-159, Mid regionalPro-Enkephalin-fragment, MRPENK. The before mentioned binder binds tosaid peptides in a bodily fluid obtained from said subject.

In one embodiment of the invention said binder is selected from thegroup comprising an antibody, an antibody fragment or a non-Ig-Scaffoldbinding to Pro-Enkephalin or fragments thereof of at least 5 aminoacids.

In a more specific embodiment the level of immunoreactive analyte byusing at least one binder that binds to a region within the amino acidsequence of Pro-Enkephalin 119-159, Mid regionalPro-Enkephalin-fragment, MRPENK (SEQ ID No. 6) in a bodily fluidobtained from said subject.

In a specific embodiment the level of Pro-Enkephalin or fragmentsthereof are measured with an immunoassay using antibodies or fragmentsof antibodies binding to Pro-Enkephalin or fragments thereof. Animmunoassay that may be useful for determining the level ofPro-Enkephalin or fragments thereof of at least 5 amino acids maycomprise the steps as outlined in Example 1. All thresholds and valueshave to be seen in correlation to the test and the calibration usedaccording to Example 1. A person skilled in the art may know that theabsolute value of a threshold might be influenced by the calibrationused. This means that all values and thresholds given herein are to beunderstood in context of the calibration used in herein (Example 1).

According to the invention the diagnostic binder to Pro-Enkephalin isselected from the group consisting of antibodies e.g. IgG, a typicalfull-length immunoglobulin, or antibody fragments containing at leastthe F-variable domain of heavy and/or light chain as e.g. chemicallycoupled antibodies (fragment antigen binding) including but not limitedto Fab-fragments including Fab minibodies, single chain Fab antibody,monovalent Fab antibody with epitope tags, e.g. Fab-V5Sx2; bivalent Fab(mini-antibody) dimerized with the CH3 domain; bivalent Fab ormultivalent Fab, e.g. formed via multimerization with the aid of aheterologous domain, e.g. via dimerization of dHLX domains, e.g.Fab-dHLX-FSx2; F(ab′)2-fragments, scFv-fragments, multimerizedmultivalent or/and multispecific scFv-fragments, bivalent and/orbispecific diabodies, BITE® (bispecific T-cell engager), trifunctionalantibodies, polyvalent antibodies, e.g. from a different class than G;single-domain antibodies, e.g. nanobodies derived from camelid or fishimmunoglobulines.

In a specific embodiment the level of Pro-Enkephalin or fragmentsthereof are measured with an assay using binders selected from the groupcomprising aptamers, non-Ig scaffolds as described in greater detailbelow binding to Pro-Enkephalin or fragments thereof.

Binder that may be used for determining the level of Pro-Enkephalin orfragments thereof exhibit an affinity constant to Pro-Enkephalin of atleast 10⁷ M⁻¹, preferred 10⁸ M⁻¹, preferred affinity constant is greaterthan 10⁹ M⁻¹, most preferred greater than 10¹⁰ M⁻¹. A person skilled inthe art knows that it may be considered to compensate lower affinity byapplying a higher dose of compounds and this measure would not leadout-of-the-scope of the invention. Binding affinity may be determinedusing the Biacore method, offered as service analysis e.g. at Biaffin,Kassel, Germany (http://www.biaffin.com/de/).

A human Pro-Enkephalin-control sample is available by ICI-Diagnostics,Berlin, Germany http://www.ici-diagnostics.com/. The assay may also becalibrated by synthetic (for our experiments we used synthetic MRPENK,SEQ ID NO. 6) or recombinant Pro-Enkephalin or fragments thereof.

In addition to antibodies other biopolymer scaffolds are well known inthe art to complex a target molecule and have been used for thegeneration of highly target specific biopolymers. Examples are aptamers,spiegelmers, anticalins and conotoxins. Non-Ig scaffolds may be proteinscaffolds and may be used as antibody mimics as they are capable to bindto ligands or antigenes. Non-Ig scaffolds may be selected from the groupcomprising tetranectin-based non-Ig scaffolds (e.g. described in US2010/0028995), fibronectin scaffolds (e.g. described in EP 1266 025;lipocalin-based scaffolds (e.g. described in WO 2011/154420); ubiquitinscaffolds (e.g. described in WO 2011/073214), transferring scaffolds(e.g. described in US 2004/0023334), protein A scaffolds (e.g. describedin EP 2231860), ankyrin repeat based scaffolds (e.g. described in WO2010/060748), microproteins preferably microproteins forming a cystineknot) scaffolds (e.g. described in EP 2314308), Fyn SH3 domain basedscaffolds (e.g. described in WO 2011/023685) EGFR-A-domain basedscaffolds (e.g. described in WO 2005/040229) and Kunitz domain basedscaffolds (e.g. described in EP 1941867).

The threshold for diagnosing kidney disease/dysfunction or fordetermining the risk of death or an adverse event may be the uppernormal range (99 percentile, 80 pmol MRPENK/L, more preferred 100 pmol/Lmore preferred 120 pmol/L.) A threshold range is useful between 75 and130 pmol MRPENK/L.

In one specific embodiment the level of Pro Enkephalin is measured withan immunoassay and said binder is an antibody, or an antibody fragmentbinding to Pro-Enkephalin or fragments thereof of at least 5 aminoacids.

In one specific embodiment the assay used comprises two binders thatbind to two different regions within the region of Pro-Enkephalin thatis aminoacid 133-140 (LKELLETG, SEQ ID No. 13) and aminoacid 152-159(SDNEEEVS, SEQ ID NO. 14) wherein each of said regions comprises atleast 4 or 5 amino acids.

In one embodiment of the assays for determining Pro-Enkephalin orPro-Enkephalin fragments in a sample according to the present inventionthe assay sensitivity of said assay is able to quantify thePro-Enkephalin or Pro-Enkephalin fragments of healthy subjects and is<15pmol/L, preferably<10 pmol/L and more preferably L<6 pmol/L.

Subject matter of the present invention is the use of at least onebinder that binds to a region within the amino acid sequence of apeptide selected from the group comprising the peptides and fragments ofSEQ ID No. 1 to 12 in a bodily fluid obtained from said subject in amethod a for (a) diagnosing or monitoring kidney function in subject or(b) diagnosing kidney dysfunction in a subject or (c) predicting ormonitoring the risk of an adverse events in a diseased subject whereinsaid adverse event is selected from the group comprising worsening ofkidney dysfunction including kidney failure, loss of kidney function andend-stage kidney disease or death due to kidney dysfunction includingkidney failure, loss of kidney function and end-stage kidney disease or(d) predicting or monitoring the success of a therapy or intervention.In one embodiment of the invention said binder is selected from thegroup comprising an antibody, an antibody fragment or a non-Ig-Scaffoldbinding to Pro-Enkephalin or fragments thereof of at least 5 aminoacids. In a specific embodiment said at least one binder binds to aregion with the sequences selected from the group comprising SEQ ID No.1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In a specific embodiment said binderdo not bind to enkephalin peptides [Met]enkephalin SEQ ID No:3, and[Leu]enkephalin. SEQ ID No:4. In a specific embodiment said at least onebinder binds to a region with the sequences selected from the groupcomprising SEQ ID No. 1, 2, 5, 6, 7, 8, 9 and 10. In another specificembodiment said at least one binder binds to a region with the sequencesselected from the group comprising SEQ ID No. 2, 5, 6, and 10. Inanother very specific embodiment said binder bind to Pro-Enkephalin119-159, Mid regional Pro-Enkephalin-fragment, MRPENK.

In a more specific embodiment the at least one binder binds to a regionwithin the amino acid sequence of Pro-Enkephalin 119-159, Mid regionalPro-Enkephalin-fragment, MRPENK (SEQ ID No. 6) in a bodily fluidobtained from said subject, more specifically to aminoacid 133-140(LKELLETG, SEQ ID No. 13) and/or aminoacid 152-159 (SDNEEEVS, SEQ ID NO.14) wherein each of said regions comprises at least 4 or 5 amino acids.

Thus, according to the present methods the level of immunoreactivity ofthe above binder is determined in a bodily fluid obtained from saidsubject. Level of immunoreactivity means the concentration of an analytedetermined quantitatively, semi-quantitatively or qualitatively by abinding reaction of a binder to such analyte, where preferably thebinder has an affinity constant for binding to the analyte of at least10⁸ M⁻¹, and the binder may be an antibody or an antibody fragment or annon.IgG scaffold, and the binding reaction is an immunoassay.

The present methods using PENK and fragments thereof, especially MRPENK,are far superior over the methods and biomarkers used according to theprior art for (a) diagnosing or monitoring kidney function in subject or(b) diagnosing kidney dysfunction in a subject or (c) predicting ormonitoring the risk of an adverse events in a diseased subject whereinsaid adverse event is selected from the group comprising worsening ofkidney dysfunction including kidney failure, loss of kidney function andend-stage kidney disease or death due to kidney dysfunction includingkidney failure, loss of kidney function and end-stage kidney disease or(d) predicting or monitoring the success of a therapy or intervention.First of all PENK and fragments thereof as biomarker for the beforementioned uses is an inflammation independent marker. That is animportant feature as most of the known kidney biomarker like NGAL andKIM are inflammation dependent, meaning if the subject has aninflammation, e.g. in sepsis, the elevation of NGAL or KIM may be eitherdue to inflammation or to kidney function/dysfunction. Thus, nodifferential diagnosis may be conducted, at least not by using a simplecut-off value (meaning one (1) cut-off value), which is independent fromthe particular patient population investigated. For NGAL and KIM eachand every patient has an “individual” threshold for kidneyfunction/dysfunction depending on the inflammation status of saidsubject which makes clinical application of these kidney markersdifficult in some diseases and impossible in others. In contrast theretoone single threshold that is independent of the inflammation status ofthe subject may be used according to the present methods for allsubjects. This makes the present methods suitable for clinical routinein contrast to the before-mentioned marker.

PENK and fragments thereof as biomarker in the methods of the presentinvention, especially MRPENK reflects “real” kidney function in contrastto NGAL and KIM, they reflect kidney damage and inflammation.

Thus, subject matter of the present invention is method for (a)diagnosing or monitoring kidney function in subject or (b) diagnosingkidney dysfunction in a subject or (c) predicting or monitoring the riskof an adverse events in a diseased subject wherein said adverse event isselected from the group comprising worsening of kidney dysfunctionincluding kidney failure, loss of kidney function and end-stage kidneydisease or death due to kidney dysfunction including kidney failure,loss of kidney function and end-stage kidney disease or (d) predictingor monitoring the success of a therapy or intervention with the beforementioned steps and features wherein an inflammation status independentthreshold is used.

Another advantage of the above methods and the use of PENK and fragmentsas biomarker in the methods for (a) diagnosing or monitoring kidneyfunction in subject or (b) diagnosing kidney dysfunction in a subject or(c) predicting or monitoring the risk of an adverse events in a diseasedsubject wherein said adverse event is selected from the group comprisingworsening of kidney dysfunction including kidney failure, loss of kidneyfunction and end-stage kidney disease or death due to kidney dysfunctionincluding kidney failure, loss of kidney function and end-stage kidneydisease or (d) predicting or monitoring the success of a therapy orintervention is that PENK and fragments as biomarker are very earlybiomarker for kidney function, kidney dysfunction, risk of an adverseevent, success of a therapy or intervention. Very early means e.g.earlier than creatinine, earlier than NGAL.

One clear indication of the superiority of PENK over creatinine comesfrom an analysis of the association of the respective concentrationsdetermined in critically ill patients on the day of admission with their7 day mortality rate: PENK concentrations of survivors differsignificantly from non-survivors, whereas this is not the case forcreatinine clearance. Mortality in such patient population is mainlydriven by loss of kidney function. Thus, the significant and muchstronger association of PENK with mortality than of creatinine clearancesupports the superiority of PENK over creatinine clearance as kidneydysfunction marker.

Subject of the present invention is also a method for (a) diagnosing ormonitoring kidney function in subject or (b) diagnosing kidneydysfunction in a subject or (c) predicting or monitoring the risk of anadverse events in a diseased subject wherein said adverse event isselected from the group comprising worsening of kidney dysfunctionincluding kidney failure, loss of kidney function and end-stage kidneydisease or death due to kidney dysfunction including kidney failure,loss of kidney function and end-stage kidney disease or (d) predictingor monitoring the success of a therapy or intervention supporting orreplacing kidney function comprising various methods of renalreplacement therapy including but not limited to hemodialysis,peritoneal dialysis, hemofiltration and renal transplantation accordingto any of the preceding embodiments, wherein the level of pro-Enkephalinor fragments thereof of at least 5 amino acids in a bodily fluidobtained from said subject either alone or in conjunction with otherprognostically useful laboratory or clinical parameters is used whichmay be selected from the following alternatives:

-   -   Comparison with the median of the level of Pro-Enkephalin or        fragments thereof of at least 5 amino acids in a bodily fluid        obtained from said subject in an ensemble of pre-determined        samples in a population of “healthy” or “apparently healthy”        subjects,    -   Comparison with a quantile of the level of Pro-Enkephalin or        fragments thereof of at least 5 amino acids in a bodily fluid        obtained from said subject in an ensemble of pre-determined        samples in a population of “healthy” or “apparently healthy”        subjects,    -   Calculation based on Cox Proportional Hazards analysis or by        using Risk index calculations such as the NRI (Net        Reclassification Index) or the IDI (Integrated Discrimination        Index).

Said additionally at least one clinical parameter may be determinedselected from the group comprising: age, NGAL, Cystatin C, CreatinineClearance, Creatinin, Urea and Apache Score.

In one embodiment of the invention said method is performed more thanonce in order to monitor the function or dysfunction or risk of saidsubject or in order to monitor the course of treatment of kidney and/ordisease. In one specific embodiment said monitoring is performed inorder to evaluate the response of said subject to preventive and/ortherapeutic measures taken.

In one embodiment of the invention the method is used in order tostratify said subjects into risk groups.

Subject matter of the invention is further an assay for determiningPro-Enkephalin and Pro-Enkephalin fragments in a sample comprising twobinders that bind to two different regions within the region ofPro-Enkephalin that is aminoacid 133-140 (LKELLETG, SEQ ID NO. 13) andaminoacid 152-159 (SDNEEEVS, SEQ ID NO. 14) wherein each of said regionscomprises at least 4 or 5 amino acids.

In one embodiment of the assays for determining Pro-Enkephalin orPro-Enkephalin fragments in a sample according to the present inventionthe assay sensitivity of said assay is able to quantify thePro-Enkephalin or Pro-Enkephalin fragments of healthy subjects and is<15pmol, preferably<10 pmol/L and more preferably L<6 pmol/L.

In one embodiment of the assays for determining Pro-Enkephalin orPro-Enkephalin fragments in a sample according to the present inventionsaid binder exhibits an binding affinity to Pro-Enkephalin of at least10⁷ M⁻¹, preferred 10⁸ M⁻¹, preferred affinity constant is lower than10⁹ M⁻¹, most preferred lower than 10¹⁰ M⁻¹. A person skilled _([K1]) inthe art knows that it may be considered to compensate lower affinity byapplying a higher dose of compounds and this measure would not leadout-of-the-scope of the invention binding affinity may be determined asdescribed above.

In one embodiment of the invention it may be a so-called POC-test(point-of-care), that is a test technology which allows performing thetest within less than 1 hour near the patient without the requirement ofa fully automated assay system. One example for this technology is theimmunochromatographic test technology.

In one embodiment of the invention such an assay is a sandwichimmunoassay using any kind of detection technology including but notrestricted to enzyme label, chemiluminescence label,electrochemiluminescence label, preferably a fully automated assay. Inone embodiment of the invention such an assay is an enzyme labeledsandwich assay. Examples of automated or fully automated assay compriseassays that may be used for one of the following systems: RocheElecsys®, Abbott Architect®, Siemens Centauer®, Brahms Kryptor®,Biomerieux Vidas®, Alere Triage®.

A variety of immunoassays are known and may be used for the assays andmethods of the present invention, these include: radioimmunoassays(“RIA”), homogeneous enzyme-multiplied immunoassays (“EMIT”), enzymelinked immunoadsorbent assays (“ELISA”), apoenzyme reactivationimmunoassay (“ARIS”), dipstick immunoassays and immuno-chromotographyassays.

In one embodiment of the invention at least one of said two binders islabeled in order to be detected.

The preferred detection methods comprise immunoassays in various formatssuch as for instance radioimmunoas say (RIA), chemiluminescence- andfluorescence-immunoassays, Enzyme-linked immunoassays (ELISA),Luminex-based bead arrays, protein microarray assays, and rapid testformats such as for instance immunochromatographic strip tests.

In a preferred embodiment said label is selected from the groupcomprising chemiluminescent label, enzyme label, fluorescence label,radioiodine label.

The assays can be homogenous or heterogeneous assays, competitive andnon-competitive assays. In one embodiment, the assay is in the form of asandwich assay, which is a non-competitive immunoassay, wherein themolecule to be detected and/or quantified is bound to a first antibodyand to a second antibody. The first antibody may be bound to a solidphase, e.g. a bead, a surface of a well or other container, a chip or astrip, and the second antibody is an antibody which is labeled, e.g.with a dye, with a radioisotope, or a reactive or catalytically activemoiety. The amount of labeled antibody bound to the analyte is thenmeasured by an appropriate method. The general composition andprocedures involved with “sandwich assays” are well-established andknown to the skilled person (23).

In another embodiment the assay comprises two capture molecules,preferably antibodies which are both present as dispersions in a liquidreaction mixture, wherein a first labelling component is attached to thefirst capture molecule, wherein said first labelling component is partof a labelling system based on fluorescence- orchemiluminescence-quenching or amplification, and a second labellingcomponent of said marking system is attached to the second capturemolecule, so that upon binding of both capture molecules to the analytea measurable signal is generated that allows for the detection of theformed sandwich complexes in the solution comprising the sample.

In another embodiment, said labeling system comprises rare earthcryptates or rare earth chelates in combination with fluorescence dye orchemiluminescence dye, in particular a dye of the cyanine type.

In the context of the present invention, fluorescence based assayscomprise the use of dyes, which may for instance be selected from thegroup comprising FAM (5- or 6-carboxyfluorescein), VIC, NED,Fluorescein, Fluoresceinisothiocyanate (FITC), IRD-700/800, Cyaninedyes, such as CY3, CY5, CY3.5, CY5.5, Cy7, Xanthen,6-Carboxy-2′,4′,7′,4,7-hexachlorofluorescein (HEX), TET,6-Carboxy-4′,5′-dichloro-2′,7′-dimethodyfluorescein (JOE),N,N,N′,N′-Tetramethyl-6-carboxyrhodamine (TAMRA), 6-Carboxy-X-rhodamine(ROX), 5-Carboxyrhodamine-6G (R6G5), 6-carboxyrhodamine-6G (RG6),Rhodamine, Rhodamine Green, Rhodamine Red, Rhodamine 110, BODIPY dyes,such as BODIPY TMR, Oregon Green, Coumarines such as Umbelliferone,Benzimides, such as Hoechst 33258; Phenanthridines, such as Texas Red,Yakima Yellow, Alexa Fluor, PET, Ethidiumbromide, Acridinium dyes,Carbazol dyes, Phenoxazine dyes, Porphyrine dyes, Polymethin dyes, andthe like.

In the context of the present invention, chemiluminescence based assayscomprise the use of dyes, based on the physical principles described forchemiluminescent materials in (24). Preferred chemiluminescent dyes areacridiniumesters.

As mentioned herein, an “assay” or “diagnostic assay” can be of any typeapplied in the field of diagnostics. Such an assay may be based on thebinding of an analyte to be detected to one or more capture probes witha certain affinity. Concerning the interaction between capture moleculesand target molecules or molecules of interest, the affinity constant ispreferably greater than 10⁸ M⁻¹.

In the context of the present invention, “binder molecules” aremolecules which may be used to bind target molecules or molecules ofinterest, i.e. analytes (i.e. in the context of the present inventionPENK and fragments thereof), from a sample. Binder molecules must thusbe shaped adequately, both spatially and in terms of surface features,such as surface charge, hydrophobicity, hydrophilicity, presence orabsence of lewis donors and/or acceptors, to specifically bind thetarget molecules or molecules of interest. Hereby, the binding may forinstance be mediated by ionic, van-der-Waals, pi-pi, sigma-pi,hydrophobic or hydrogen bond interactions or a combination of two ormore of the aforementioned interactions between the capture moleculesand the target molecules or molecules of interest. In the context of thepresent invention, binder molecules may for instance be selected fromthe group comprising a nucleic acid molecule, a carbohydrate molecule, aPNA molecule, a protein, an antibody, a peptide or a glycoprotein.Preferably, the binder molecules are antibodies, including fragmentsthereof with sufficient affinity to a target or molecule of interest,and including recombinant antibodies or recombinant antibody fragments,as well as chemically and/or biochemically modified derivatives of saidantibodies or fragments derived from the variant chain with a length ofat least 12 amino acids thereof.

Chemiluminescent label may be acridinium ester label, steroid labelsinvolving isoluminol labels and the like.

Enzyme labels may be lactate dehydrogenase (LDH), creatinekinase (CPK),alkaline phosphatase, aspartate aminotransferace (AST), alanineaminotransferace (ALT), acid phosphatase, glucose-6-phosphatedehydrogenase and so on.

In one embodiment of the invention at least one of said two binders isbound to a solid phase as magnetic particles, and polystyrene surfaces.

In one embodiment of the assays for determining Pro-Enkephalin orPro-Enkephalin fragments in a sample according to the present inventionsuch assay is a sandwich assay, preferably a fully automated assay. Itmay be an ELISA fully automated or manual. It may be a so-calledPOC-test (point-of-care). Examples of automated or fully automated assaycomprise assays that may be used for one of the following systems: RocheElecsys®, Abbott Architect®, Siemens Centauer®, Brahms Kryptor®,Biomerieux Vidas®, Alere Triage®. Examples of test formats are providedabove.

In one embodiment of the assays for determining Pro-Enkephalin orPro-Enkephalin fragments in a sample according to the present inventionat least one of said two binders is labeled in order to be detected.Examples of labels are provided above.

In one embodiment of the assays for determining Pro-Enkephalin orPro-Enkephalin fragments in a sample according to the present inventionat least one of said two binders is bound to a solid phase. Examples ofsolid phases are provided above.

In one embodiment of the assays for determining Pro-Enkephalin orPro-Enkephalin fragments in a sample according to the present inventionsaid label is selected from the group comprising chemiluminescent label,enzyme label, fluorescence label, radioiodine label. A further subjectof the present invention is a kit comprising an assay according to thepresent invention wherein the components of said assay may be comprisedin one or more container.

In one embodiment subject matter of the present invention is apoint-of-care device for performing a method according to the inventionwherein said point of care device comprises at least one antibody orantibody fragment directed to either aminoacid 133-140 (LKELLETG, SEQ IDNo. 13) or aminoacid 152-159 (SDNEEEVS, SEQ ID NO. 14) wherein each ofsaid regions comprises at least 4 or 5 amino acids.

In one embodiment subject matter of the present invention is apoint-of-care device for performing a method according to the inventionwherein said point of care device comprises at least two antibodies orantibody fragments directed to aminoacid 133-140 (LKELLETG, SEQ ID No.13) and aminoacid 152-159 (SDNEEEVS, SEQ ID NO. 14) wherein each of saidregions comprises at least 4 or 5 amino acids.

In one embodiment subject matter of the present invention is a kit orperforming a method according to the invention wherein said point ofcare device comprises at least one antibody or antibody fragmentdirected to either aminoacid 133-140 (LKELLETG, SEQ ID No. 13) oraminoacid 152-159 (SDNEEEVS, SEQ ID NO. 14) wherein each of said regionscomprises at least 4 or 5 amino acids.

In one embodiment subject matter of the present invention is a kit forperforming a method according to the invention wherein said point ofcare device comprises at least two antibodies or antibody fragmentsdirected to aminoacid 133-140 (LKELLETG, SEQ ID No. 13) and aminoacid152-159 (SDNEEEVS, SEQ ID NO. 14) wherein each of said regions comprisesat least 4 or 5 amino acids.

EXAMPLES Example 1

Development of Antibodies

Peptides

Peptides were synthesized (JPT Technologies, Berlin, Germany).

Peptides/Conjugates for Immunization:

Peptides for immunization were synthesized (JPT Technologies, Berlin,Germany) with an additional N-terminal Cystein residue for conjugationof the peptides to bovine serum albumin (BSA). The peptides werecovalently linked to BSA by using Sulfo-SMCC (Perbio-science, Bonn,Germany). The coupling procedure was performed according to the manualof Perbio.

TABLE 1 Peptide for immunization Pro-Enkephalin-sequence (C)DAEEDD119-125 (C)EEDDSLANSSDLLK 121-134 (C)LKELLETG 133-140(C)TGDNRERSHHQDGSDNE 139-155 (C)SDNEEEVS 152-159

The antibodies were generated according to the following method:

A BALB/c mouse was immunized with 100 μg peptide-BSA-conjugate at day 0and 14 (emulsified in 100 μl complete Freund's adjuvant) and 50 μg atday 21 and 28 (in 100 μl incomplete Freund's adjuvant). Three daysbefore the fusion experiment was performed, the animal received 50 μg ofthe conjugate dissolved in 100 μl saline, given as one intraperitonaland one intravenous injection.

Spenocytes from the immunized mouse and cells of the myeloma cell lineSP2/0 were fused with 1 ml 50% polyethylene glycol for 30 s at 37° C.After washing, the cells were seeded in 96-well cell culture plates.Hybrid clones were selected by growing in HAT medium [RPMI 1640 culturemedium supplemented with 20% fetal calf serum and HAT-supplement]. Aftertwo weeks the HAT medium is replaced with HT Medium for three passagesfollowed by returning to the normal cell culture medium.

The cell culture supernatants were primary screened for antigen specificIgG antibodies three weeks after fusion. The positive testedmicrocultures were transferred into 24-well plates for propagation.After retesting the selected cultures were cloned and recloned using thelimiting-dilution technique and the isotypes were determined.

(Lane, R. D. “A short-duration polyethylene glycol fusiontechnique forincreasing production of monoclonal antibody-secreting hybridomas”, J.Immunol. Meth. 81: 223-228; (1985), Ziegler, B. et al. “Glutamatedecarboxylase (GAD) is not detectable on the surface of rat islet cellsexamined by cytofluorometry and complement-dependent antibody-mediatedcytotoxicity of monoclonal GAD antibodies”, Horm. Metab. Res. 28: 11-15,(1996)).

Monoclonal Antibody Production

Antibodies were produced via standard antibody production methods (Marxet al., Monoclonal Antibody Production (1997), ATLA 25, 121) andpurified via Protein A-chromatography. The antibody purities were>95%based on SDS gel electrophoresis analysis.

Labelling and Coating of Antibodies.

All antibodies were labelled with acridinium ester according thefollowing procedure:

Labelled compound (tracer): 100 μg (100 μl) antibody (1 mg/ml in PBS, pH7.4), was mixed with 10 μl Acridinium NHS-ester (1 mg/ml inacetonitrile, InVent GmbH, Germany) (EP 0353971) and incubated for 20min at room temperature. Labelled antibody was purified bygel-filtration HPLC on Bio-Sil SEC 400-5 (Bio-Rad Laboratories, Inc.,USA) The purified labelled antibody was diluted in (300 mmol/lpotassiumphosphate, 100 mmol/l NaCl, 10 mmol/l Na-EDTA, 5 g/l bovineserum albumin, pH 7.0). The final concentration was approx. 800.000relative light units (RLU) of labelled compound (approx. 20 ng labeledantibody) per 200 μl. Acridiniumester chemiluminescence was measured byusing an AutoLumat LB 953 (Berthold Technologies GmbH & Co. KG).

Solid Phase Antibody (Coated Antibody):

Solid phase: Polystyrene tubes (Greiner Bio-One International AG,Austria) were coated (18 h at room temperature) with antibody (1.5 μgantibody/0.3 ml 100 mmol/l NaCl, 50 mmol/l Tris/HCl, pH 7.8). Afterblocking with 5% bovine serum albumine, the tubes were washed with PBS,pH 7.4 and vacuum dried.

Antibody Specificity

TABLE 2 Peptide for immunization Pre-Pro-Enkephalin-sequenceAntibody name (C)DAEEDD 119-125 NT-MRPENK (C)EEDDSLANSSDLLK 121-134NM-MRPENK (C)LKELLETG 133-140 MR-MRPENK (C)TGDNRERSHHQDGSDNE 139-155MC-MRPENK (C)SDNEEEVS 152-159 CT-MRPENK

Antibody cross-reactivities were determined as follows:

1 ug peptide in 300 μl PBS, pH 7.4 was pipetted into Polystyrene tubesand incubated for 1 h at room temperature. After incubation the tubeswere washed 5 times (each 1 ml) using 5% BSA in PBS, pH 7.4. Each of thelabelled antibodies were added (300 μl in PBS, pH 7.4, 800.000 RLU/300μl) an incubated for 2 h at room temperature, After washing 5 times(each 1 ml of washing solution (20 mmol/l PBS, pH 7.4, 0.1% Triton X100), the remaining luminescence (labelled antibody) was quantifiedusing the AutoLumat Luminumeter 953. MRPENK-peptide was used asreference substance (100%).

The crossreactivities of the different antibodies are listed in table 3.

TABLE 3 DAEE EEDDSLANSS LKELLE TGDNRERSHH SDNEEE MRPENK Antibody DD DLLKTG QDGSDNE VS (SEQ ID NO. 6) NT-MRPENK    121   10 <1 <1 <1 100NM-MRPENK <1   98 <1 <1 <1 100 MR-MRPENK <1 <1    105 <1 <1 100MC-MRPENK <1 <1 <1    115 <1 100 CT-MRPENK <1 <1 <1 <1   95 100

All antibodies bound the MRPENK peptide, comparable to the peptideswhich were used for immunization. Except for NT-MRPENK-antibody (10%cross reaction with EEDDSLANSSDLLK), no antibody showed a cross reactionwith MR-PENK fragments not used for immunization of the individualantibody.

Pro-Enkephalin Immunoassay:

50 μl of sample (or calibrator) was pipetted into coated tubes, afteradding labeled antibody (200 ul), the tubes were incubated for 2 h at18-25° C. Unbound tracer was removed by washing 5 times (each 1 ml) withwashing solution (20 mmol/l PBS, pH 7.4, 0.1% Triton X-100). Tube-boundlabelled antibody was measured by using the Luminumeter 953. Using afixed concentration of 1000 pmol/of MRPENK. The signal (RLU at 1000 pmolMRPENK/1) to noise (RLU without MRPENK) ratio of different antibodycombinations is given in table 4. All antibodies were able to generate asandwich complex with any other antibody. Surprisingly, the strongestsignal to noise ratio (best sensitivity) was generated by combining theMR-MRPENK- and CT-MRPENK antibody. Subsequently, we used this antibodycombination to perform the MRPENK-immunoassay for furtherinvestigations. MR-MRPENK antibody was used as coated tube antibody andCT-MRPENK antibody was used as labelled antibody.

TABLE 4 Solid phase antibody NT-MRPENK NM-MRPENK MR-MRPENK MC-MRPENKCT-MRPENK Labelled antibody NT-MRPENK /  27  212 232   <1 NM-MRPENK  36/  451 487   <1 MR-MRPENK 175 306 / 536 1050 MC-MRPENK 329 577  542 /  <1 CT-MRPENK  <1 615 1117 516 /Calibration:

The assay was calibrated, using dilutions of synthetic MRPENK, dilutedin 20 mM K2PO4, 6 mM EDTA, 0.5% BSA, 50 μM Amastatin, 100 μM Leupeptin,pH 8.0. Pro-Enkephalin control plasma is available at ICI-diagnostics,Berlin, Germany.

FIG. 1 shows a typical Pro-Enkephalin dose/signal curve.

The assay sensitivity was 20 determinations of 0-calibrator (no additionof MRPENK)+2SD) 5.5 pmol/L.

Creatinine Clearance

Creatinine clearance was determined using the MDRD formula (see Levey etal, 2009).

Example 2

PENK in Healthy Subjects

Healthy subjects (n=4211, average age 56 years) were measured using theMRPENK assay. The mean value was 44.7 pmol MRPENK/L, the lowest valuewas 9 pmol/L and the 99^(th) percentile was 80 pmol/L. Since the assaysensitivity was 5.5 pmol/L, 100% of all healthy subjects were detectableusing the described MRPENK assay (see FIG. 2).

Pro-Enkephalin correlates with Creatinine Clearance in healthy subjectswith normal kidney function.

Surprisingly, Pro-Enkephalin was negatively correlated with CreatinineClearance in healthy subjects (r=−0.33, p<0.0001), see FIG. 3. Thecoefficient of correlation was slightly stronger in male than in females(r=−0.34 vs −0.29, both p<0.0001). These data indicating a strongassociation between PENK and kidney function.

FIG. 3: correlation of creatinine clearance vs. PENK in healthysubjects. Y axis: quartiles of Creatinine Clearance, x axis: quartilesof PENK.

Example 3

Correlation of PENK and Kidney Function (Creatinine Clearance) inPatients with Chronic and Acute Diseases.

TABLE 5 Disease r-value p-value Chronic Heart Failure −0.55 <0.0001 N =122 Acute Heart Failure −0.68 <0.0001 N = 149 Acute MyocardialInfarction −0.82 <0.0001 N = 78 Sepsis −0.74 <0.0001 N = 101 SIRS −0.79<0.0001 N = 109PENK correlated always significantly with creatinine clearance, in acutediseases the correlation was stronger than in chronic diseases or inhealthy subjects.

Example 4: PENK in Critical Ill Patients

To investigate the diagnostic performance of PENK for diagnosis ofkidney failure in acute clinical settings, we performed the followingclinical study:

Clinical Study

101 ED patients fulfilling the definition of sepsis (Crit Care Med. 2008January; 36(1):296-327.) were subsequently hospitalized (average 5 daysof hospitalization) and received a standard of care treatment.EDTA-plasma was generated from day 1 (ED presentation) and one sampleeach day during hospital stay. The time to freeze samples for lateranalyte-measurement was less than 4 h.

Patient characteristics are summarized in table 6:

TABLE 6 in hospital all deaths discharged Variable (n = 101) (n = 27) (n= 74) p-value Demographics Gender - male 60 (60) 13 (48) 47 (64) 0.163Age - median [IQR] 78 [72-72] 77 [71.25-83] 80 [75-84.5] 0.142Examination variables BP systolic (mmHg) - median [IQR] 115 [100-100]120 [106.25-138.75] 105 [80-120] 0.001 BP diastolic (mmHg) - median[IQR] 65 [60-60] 65 [60-85] 60 [50-70] 0.002 HR - median [IQR] 100[94-94] 100 [94-114.75] 100 [93.5-107.5] 0.407 RR - median [IQR] 24[22-22] 24 [22-28] 26 [24-28] 0.069 MAP (mmHg) - median [IQR] 83.3[74-74] 83.3 [77.62-100.75] 81.6 [63.5-89] 0.026 concomitant diseasesCardiovascular - yes 26 (25.7) 9 (33.3) 17 (23) 0.311 Hypertensive - yes47 (46.5) 13 (48.1) 34 (45.9) 1.000 Diabetes - yes 35 (34.7) 9 (33.3) 26(35.1) 1.000 Cancere - yes 13 (12.9) 3 (11.1) 10 (13.5) 1.000 routinelabaratory variables Blood culture - yes 31 (31) 5 (19) 26 (35) 0.246negative 15 (16.3) 2 (8) 13 (19.4) positive 16 (17.4) 3 (12) 13 (19.4)Creatinine clearance (ml/min) - median 48 [23.25-23.25] 56 [29.25-80]31.5 [14.75-66] 0.043 [IQR] Creatinine - median [IQR] 1.3 [0.9-0.9] 1.25[0.9-2.08] 1.8 [1-3.15] 0.080 UREA - median [IQR] 36 [21-21] 31.5[20-53.25] 51 [42-87] 0.004 GCS - median [IQR] 15 [10-10] 15 [12.5-15] 8[8-11] <0.001 Pcr - median [IQR] 16 [6.6-6.6] 14.5 [6.7-23.7] 17.35[6.6-28.05] 0.846 Gluco - median [IQR] 113.5 [94.5-94.5] 110 [95.5-144]128 [94-160.5] 0.400 biliru - median [IQR] 0.9 [0.71-0.71] 0.9[0.7-1.03] 0.91 [0.77-1.18] 0.534 GR - median [IQR] 3.8 [3.3-3.3] 3.8[3.2-4.3] 3.7 [3.4-4.2] 0.684 GB - median [IQR] 12700 [6774-6774] 13100[8115-17565] 11920 [25.55-18790] 0.343 PLT - median [IQR] 213 [150-150]217 [154.75-301] 185 [130-236.5] 0.113 HCT - median [IQR] 32 [28-28]31.5 [28-37] 34 [31.25-39.5] 0.149 Leuco/Neutr (%) - median [IQR] 87[80-80] 86 [78.25-89.95] 91 [87-93.05] 0.001 HB - median [IQR] 10.4[9.47-9.47] 10.15 [9.3-12.4] 10.85 [9.9-12.67] 0.220 Na - median [IQR]137 [134-134] 137 [133-141] 139 [134-144.5] 0.204 K - median [IQR] 3.9[3.5-3.5] 3.9 [3.6-4.3] 3.9 [3.3-5.1] 0.982 INR - median [IQR] 1.19[1.1-1.1] 1.19 [1.1-1.4] 1.18 [1.04-1.36] 0.731 TC - median [IQR] 38.4[36-36] 38.5 [38.12-38.7] 36 [35.55-38.5] <0.001 SAO2 - median [IQR] 94[90-90] 95 [90.25-97] 93 [88.5-95.5] 0.119 pH - median [IQR] 7.45[7.38-7.38] 7.46 [7.4-7.5] 7.4 [7.24-7.4] <0.001 PO2 - median [IQR] 67[56-56] 66.5 [56-78] 67 [56.5-79.5] 0.806 PCO2 - median [IQR] 36 [32-32]37.5 [33-43.75] 34 [30-41] 0.245 Lact - median [IQR] 1.5 [1-1] 1.3[0.83-1.9] 2.5 [1.4-4.15] <0.001 Bic - median [IQR] 23.5 [21-21] 24.25[21.43-28] 21 [17.35-23.25] 0.001 FiO2 (%) - median [IQR] 21 [21-21] 21[21-23.25] 24 [21-45] <0.001 other Acute organ disfunction - yes 39(43.3) 16 (64) 23 (35.4) 0.021 Apache score (%) - median [IQR] 19[12.5-12.5] 14.65 [12.12-20.38] 32 [20-39] <0.001 Days hospitalized -median [IQR] 5 [2-2] 6 [4-7] 2 [1-6] 0.003 treatment at baselineDiuresis (cc) - median [IQR] 900 [600-600] 1000 [700-1200] 450[200-1025] <0.001 Steroids - yes 16 (15.8) 4 (14.8) 12 (16.2) 1.000Vasopressors - yes 18 (17.8) 13 (48.1) 5 (6.8) <0.001 Antibiotics - yes101 (100) 27 (100) 74 (100) 1.000 Fluid therapy - yes 101 (100) 27 (100)74 (100) 1.000

26.7% of all patients died during hospital stay and are counted astreatment non responder,

73.3% of all patients survived the sepsis and are counted as treatmentresponder.

53% off all patients presenting with sepsis had an non-normal PENKvalue>80 pmol/L (99 percentile), indicating PENK not to be a marker forthe infection.

Results of Clinical Study

PENK highly correlated to creatinine clearance (r=−0.74, p<0.0001, FIG.4).

PENK Diagnoses Kidney Dysfunction:

Kidney dysfunction was defined based on the RIFLE criteria (Venkatamaranand Kellum, 2007). Patients were counted as kidney dysfunction if any ofthe RIFLE classification factors was fulfilled. Within the study cohort,we determined the RIFLE within 90 subjects at day 1 (presentation atED), 39 patients fulfilled RIFLE classification (had risk of kidneydisease, kidney injury, kidney failure loss of kidney function orend-stage kidney disease) and 51 patients had no kidney dysfunction.Increased PENK was significantly (p=<0.0001) correlated with kidneydysfunction (AUC: 0.868). (FIGS. 5 and 6)

To compare the diagnostic value for kidney dysfunction, we used NGAL asreference marker (Soni et al, 2010). NGAL was measured, using acommercially ELISA (NGAL Elisa kit, Bioporto, Gentofte, Denmark).

NGAL, like PENK, was significantly increased in patients with kidneydysfunction (p<0.0001), the AUC for diagnosis of kidney dysfunction was0.809. (FIGS. 7 and 8)

Comparing PENK and NGAL showed a strong superiority of PENK vs NGAL fordiagnosis of kidney dysfunction: the Chi2 value of PENK was 45.32 vs.32.21 for NGAL, indicating a 40% improvement of diagnostic quality(specificity and sensitivity) by PENK. (Table 7)

TABLE 7 Model Model N Events Chi2 d.f. LR p-value C index [95-CI] PCT 7634 13.02 1 0.00031 0.721 [0.602, 0.839] Apache 90 39 28.58 1 <0.000010.778 [0.681, 0.874] NGal 90 39 32.21 1 <0.00001 0.809 [0.723, 0.896]PENK 90 39 45.32 1 <0.00001 0.868 [0.796, 0.94]Initial PENK is Highly Prognostic.

We correlated the initial PENK value with the in hospital mortality andcompared PENK with APACHE 2 sepsis score (see Knaus et al, 1985, 2001)and creatinine clearance. PENK is highly prognostic for sepsis outcome(see FIG. 9) and comparable to APACHE 2 score (AUC/C index 0.744 (PENK)and 0.783 (Apache). There is a significant added information if PENK andAPACHE 2 are combined (combined AUC: 0.794 FIG. 10). PENK issubstantially stronger in prognosis than the creatinine clearance (AUC0.638). Surprisingly, the prognostic value of PENK was stronger afterthe first day of ICU-treatment (AUC 0.79).

Cut Off-Analysis for in Hospital Death Prognosis Using Baseline Sampleand 1 Sample after 1 Day of ICU Treatment.

Since the prognostic power of PENK was further improved one day afterstarting ICU treatment, we analyzed the PENK in serial measurements ofday before ICU-treatment and 1 day after starting ICU treatment. Toillustrate the clinical performance, we used a simple cut off analysisat a cut off value of 100 pmol/L.

If patients are below the cut off at hospital presentation and remainbelow the cut off after initiating ICU treatment, the mortality was 11%(well treated before and during hospitalization). If PENK was above thecut off at both time points, the mortality was about 5 times higher(52.5%) (not responding to treatment) and if patients present with PENKvalues above 100 pmol/l and reducing their PENK levels below 100 pmol/lduring ICU treatment the mortality was 0 (treatment responder). Thesedata indicate a strong association of PENK and treatment success,supporting its use for therapy follow up (serial testing).

TABLE 8 N patients mortality died vs all PENK >100 pmol/l presentationand first 52.5% 21/40 day after ICU treatment PENK >100 pmol/l atpresentation and <100   0% 0/7 pmol/l first day after ICU treatment PENK<100 pmol/l at presentation and  11%  6/54 first day of ICU treatmentFIG. 11 a-d: Examples of Patient Follow Up Measurements.

-   a) A patient (survivor) with initial PENK<100 pmol/L and    remained<100 pmol/L during hospital stay.-   b) A patient (died during hospital stay) with initial PENK>100    pmol/L and was not reduced to values<100 pmol/L.-   c) A patient (died during hospital stay) with initial PENK>100    pmol/L and was not reduced to values<100 pmol/L.-   d) A patient (survivor) with initial PENK>100 pmol/L, the PENK value    declined to values<100 pmol/L within one day of ICU treatment.

Example 5: The Use of Serial Measurement of PENK

In the patient population described in example 4 (patients with sepsis,severe sepsis or septic shock) plasma PENK was measured on the day ofadmission and on the following day (day 1). Using a simple cut-off valueof 100 pmol/L, which is close to the 99th percentile of the normalrange, the population was segmented in two groups (above and below 100pmol/L) and the corresponding 7 day survival rates were depicted inKaplan-Meier-Plots (FIGS. 16 a) and b)). Patients with a PENKconcentration below 100 pmol/L on the day of admission, whose PENKconcentration remained below 100 pmol/L on day 1, had a high survivalrate of 87%, whereas, when their PENK concentration increased over 100pmol/L on day 1, the survival rate was lowered to 67%. In contrast,patients with a PENK concentration above 100 pmol/L on the day ofadmission, whose PENK concentration remained above 100 pmol/L on day 1,had a poor survival rate of only 50%, whereas, when their PENKconcentration decreased below 100 pmol/L on day 1, the survival rate was100%.

Example 6

Using the plasma PENK concentrations determined in the patientpopulation described in example 4 (patients with sepsis, severe sepsisor septic shock) on the day of admission, it was analyzed bymultivariable linear regression analysis, which parameters/variablesdetermine to which extent the PENK concentrations. In FIG. 17 thepartial R2 are depicted. The analysis demonstrates that measures ofkidney function (in the case shown creatinine clearance) are by far thestrongest determinants for PENK concentrations.

TABLE 9 Association of variables determined in the patient population asdescribed in example 4 on the day of admission with the 7 day mortality.deaths within 7 day Variable - median all 7 days survivor [IQR) (n =101) (n = 28) (n = 73) p-value PENK (pmol/L)  87 [50-205) 209 [77-499) 75 [47-124) <0.001 Creatinine clearance 48 [23-77) 33 [15-69) 56[29-81) 0.071 (ng/mL) Apache score 16 [13-21) 23 [18-27) 14 [12-18)<0.001 (points)PENK in Males

Using PENK as prognostic marker, PENK at first day (presentation at ED)was even stronger in prognosis of in hospital death in the malepopulation (AUC 0.849, FIG. 12), a combination of PENK and Apacheresulted in an AUC of 0.89 vs 0.837 Apache alone (FIG. 13). Thecombination of PENK and creatinine clearance generated a superiorprognostic value of AUC 0.91 vs 0.721 for creatinine clearance alone(FIG. 14). As for the whole patient population, the prognostic value ofPENK was stronger after the first day of ICU-treatment (day 2, AUC0.872).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: shows a typical ProEnkephalin dose/signal curve. Standard curveproEnkephalin

FIG. 2: frequence distribution of Pro Enkephalin in a healthy population(n=4211) The mean value of PENK was 44.7 pmol/L, standarddeviation=1.27, the 99 percentile (upper normal range) was 80 pmolPENK/L. FIG. 2 shows the LN values of PENK.

FIG. 3: Correlation of creatinine clearance vs. PENK in healthysubjects. Y axis: quartiles of Creatinine Clearance, x axis: quartilesof PENK.

FIG. 4: PENK highly correlated to creatinine clearance (r=−0.74,p<0.0001).

FIG. 5: Increased PENK was significantly correlated with kidneydysfunction.

FIG. 6: A receiver/operator curve (ROC) for Pro-Enkephalin and thediagnosis of Kidney Dysfunction according the RIFLE criteria (seeabove). The area under the curve (AUC) was 0.868, indicating a strongdiagnostic power of Pro-Enkephalin for Kidney Dysfunction.

FIG. 7: Increased NGAL was significantly increased in patients withkidney dysfunction. The normal ranges of NGAL (range 0.037-0.106 μg/mL;http://www.bioporto.com/products/bioporto_diagnostics/ngal_elisa_kits/ngal_rapid_elisa_kit_ce_ivd)is indicated by a shadowed area in the graph.

FIG. 8: A receiver/operator curve (ROC) for NGAL and the diagnosis ofKidney Dysfunction according the RIFLE criteria (see above). We usedNGAL as a reference marker for Kidney dysfunction. The AUC was 0.809,substantially lower than for Pro-Enkephalin (AUC 0.868, FIG. 6),indicating the incremental value of Pro-Enkephalin.

FIG. 9: PENK is highly prognostic for sepsis outcome

FIG. 10: There is a significant added information if PENK and APACHE 2are combined

FIG. 11a ): A patient (survivor) with initial PENK<100 pmol/L andremained<100 pmol/L during hospital stay

FIG. 11B): A patient (died during hospital stay) with initial PENK>100pmol/L and was not reduced to values<100 pmol/L

FIG. 11c ): A patient (died during hospital stay) with initial PENK>100pmol/L and was not reduced to values<100 pmol/L

FIG. 11d ): A patient (survivor) with initial PENK>100 pmol/L, the PENKvalue declined to values<100 pmol/L within one day of ICU treatment

FIG. 12: PENK at first day (presentation at ED) was even stronger inprognosis of in hospital death in the male population

FIG. 13: A combination of PENK and Apache resulted in an AUC of 0.89 vs.0.837 Apache alone

FIG. 14: The combination of PENK and creatinine clearance generated asuperior prognostic value of AUC 0.91 vs. 0.721 for creatinine clearancealone

FIG. 15A/FIG. 15B: Concentrations of plasma PENK (A) and NGAL (B),respectively, in septic patients categorized by grade of acute kidneydysfunction. 0=no kidney dysfunction; R=Risk; I=Injury; F=Failure;L=Loss. The categories are defined as follows(http://en.wikipedia.org/wiki/Acute_kidney_injury): Risk: GFRdecrease>25%, serum creatinine increased 1.5 times or urine productionof<0.5 ml/kg/hr for 6 hours; Injury: GFR decrease>50%, doubling ofcreatinine or urine production<0.5 ml/kg/hr for 12 hours; Failure: GFRdecrease>75%, tripling of creatinine or creatinine>355 μmol/l (with arise of>44) (>4 mg/dl) OR urine output below 0.3 ml/kg/hr for 24 hours;Loss: persistent AKI or complete loss of kidney function for more than 4weeks. Normal ranges of PENK (see FIG. 2) and NGAL (range 0.037-0.106μg/mL;http://www.bioporto.com/products/bioporto_diagnostics/ngal_elisa_kits/ngal_rapid_elisa_kit_ce_ivd)concentrations are indicated by shadowed areas in the graphs. The figuredemonstrates that NGAL concentrations are massively elevated in septicpatients even when they have no kidney dysfunction, whereas this is notthe case for PENK.

FIG. 16A/FIG. 16B: Survival rates of critically ill patients dependingon their plasma PENK concentrations on the day of admission and on thenext day (day 1). Panel A: On the left hand side, the Kaplan-Meier-Plotis shown for those patient subpopulations with a PENK concentration onadmission of above and below 100 pmol/L, respectively. On the right handside the Kaplan-Meier-Plot is shown for those patient subpopulationswith a PENK concentration on day 1 of above and below 100 pmol/L,respectively, who had a PENK concentration below 100 pmol/L on the dayof admission. Panel B: On the left hand side, the Kaplan-Meier-Plot isshown for those patient subpopulations with a PENK concentration onadmission of above and below 100 pmol/L, respectively. On the right handside the Kaplan-Meier-Plot is shown for those patient subpopulationswith a PENK concentration on day 1 of above and below 100 pmol/L,respectively, who had a PENK concentration above 100 pmol/L on the dayof admission.

FIG. 17: Multivariable linear regression predicting PENK. Note: BP,Creatinine and Urea were left out due to high correlation with MAP orcreatinine clearance. The linear regression was calculated using thevariables listed as follows:Log(PENK)=a*CreaClearance+b*Cardiovasc+c*MAP+etc. Partial R2 gives thedegree up to which each variable contributes to PENK, i.e. CreaClearance is strongest and has a partial R2 of slightly above 0.15, i.e.crea clearance accounts for about 15% of the variability that youobserve in PENK. Importantly, age, gender, etc. do not have asignificant influence on PENK concentrations.

The invention claimed is:
 1. A method which comprises: selecting asubject who suffers from kidney disease and who has not suffered astroke; determining and recording the level of Pro-Enkephalin orfragments thereof in a bodily fluid obtained from said subject withkidney disease using a binder to Pro-Enkephalin or a fragment thereofand wherein said Pro-Enkephalin or fragment thereof is one or more ofSEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 8,SEQ ID No. 9, SEQ ID No. 10 or SEQ ID No. 11 and wherein said binderdoes not bind to SEQ ID No: 3 and determining at least one additionalclinical parameter of said subject which is age, BUN (blood ureanitrogen), NGAL neutrophil gelatinase-associated lipocalin, CreatinineClearance, Creatinine, urea, or Apache Score.
 2. A method according toclaim 1 wherein diseased subject suffers from end stage kidney disease.3. A method according to claim 1 wherein said binder does not bind toSEQ ID No:
 4. 4. A method according to claim 1, wherein said binder isused in an assay for determining the level of Pro-Enkephalin orfragments thereof and the sensitivity of said assay is able to quantifythe Pro-Enkephalin or Pro-Enkephalin fragments of healthy subjects andis<15 pmol/L.
 5. A method according to claim 1 wherein said bodily fluidis blood, serum, plasma, urine, cerebro spinal liquid (csf) or saliva.6. A method according to claim 1, wherein said least one additionalclinical parameter is BUN, NGAL, Creatinine Clearance or Apache Score.7. A method according to claim 1, wherein said binder binds to a regionwithin an amino acid sequence selected from the group consisting of SEQID No. 2, 5, 6, and
 10. 8. A method according to claim 1, wherein saidbinder binds to SEQ ID No.
 6. 9. A method comprising determining thelevel of Pro-Enkephalin fragments in a bodily fluid obtained from asubject using a binder to said Pro-Enkephalin fragments; and determiningat least one additional clinical parameter from said subject that isage, BUN, NGAL, Creatinine Clearance, Creatinine or Apache Score,correlating said level of said Pro-Enkephalin fragments and at least oneadditional clinical parameter with kidney function in said subject, orkidney dysfunction in said subject, wherein an elevated level above acertain threshold is predictive or diagnostic for kidney dysfunction insaid subject, or risk of an adverse event in a subject with kidneydisease, wherein an elevated level above a certain threshold ispredictive for an enhanced risk of said adverse events, or success of atherapy or intervention in a subject with kidney disease, wherein alevel below a certain threshold is predictive for a success of therapyor intervention, wherein said Pro-Enkephalin fragments is one or more ofSEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 8,SEQ ID No. 9, SEQ ID No. 10 or SEQ ID No. 11 and wherein said binderbinds to a region within an amino acid sequence selected from the groupconsisting of SEQ ID No. 1, 2, 5, 6, 7, 8, 9, 10 and 11 and does notbind to enkephalin peptides [Met]enkephalin SEQ ID No:3.
 10. A methodaccording to claim 9 wherein the binder is used in an assay fordetermining the level of Pro-Enkephalin fragments and whereinsensitivity of said assay is able to quantify the Pro-Enkephalinfragments of healthy subjects and is<15 pmol/L.
 11. A method accordingto claim 9, wherein said Pro-Enkephalin fragments is SEQ ID No. 1 andoptionally, one or more of , SEQ ID No. 2, SEQ ID No. 5, SEQ ID No. 6,SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10 or SEQ ID No.
 11. 12. A methodaccording to claim 9, wherein said binder does not bind to enkephalinpeptides [Met]enkephalin SEQ ID No: 3, and [Leu]enkephalin. SEQ ID No:4.
 13. A method according to claim 9, wherein said binder binds to aregion within an amino acid sequence selected from the group consistingof SEQ ID No. 2, 5, 6, and
 10. 14. A method according to claim 9,wherein said binder binds to an amino acid sequence within SEQ ID No. 6.15. A method for (a) diagnosing or monitoring kidney function in asubject or (b) diagnosing kidney dysfunction in a subject or (c)predicting or monitoring the risk of an adverse events in a subject,wherein said adverse event is selected from the group comprisingworsening of kidney dysfunction including kidney failure, loss of kidneyfunction and end-stage kidney disease or death due to kidney dysfunctionincluding kidney failure, loss of kidney function and end-stage kidneydisease or (d) predicting or monitoring the success of a therapy orintervention comprising determining the level of Pro-Enkephalin orfragments thereof in a bodily fluid obtained from said subject; anddetermining at least one additional clinical parameter that is age, BUN,NGAL, Creatinine Clearance, Creatinine or Apache Score; and (a)correlating said level of Pro-Enkephalin or fragments and at least oneadditional clinical parameter thereof with kidney function in saidsubject, or (b) correlating said level of Pro-Enkephalin or fragmentsthereof and at least one additional clinical parameter with kidneydysfunction, wherein an elevated level above a certain threshold ispredictive or diagnostic for kidney dysfunction in said subject, or (c)correlating said level of Pro-Enkephalin or fragments thereof and atleast one additional clinical parameter with said risk of an adverseevent in a subject with kidney disease, wherein an elevated level abovea certain threshold is predictive for an enhanced risk of said adverseevents, or (d) correlating said level of Pro-Enkephalin or fragmentsthereof and at least one additional clinical parameter with success of atherapy or intervention in a subject with kidney disease, wherein alevel below a certain threshold is predictive for a success of therapyor intervention, wherein said Pro-Enkephalin or fragment thereof is oneor more of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 5, SEQ ID No. 6, SEQID No. 8, SEQ ID No. 9, SEQ ID No. 10 or SEQ ID No. 11, wherein thelevel of Pro-Enkephalin or fragments thereof is determined by using anassay comprising a binder that does not bind to enkephalin peptides[Met]enkephalin SEQ ID No: 3, wherein said binder is an antibody, anantibody fragment, or a non-Ig-Scaffold.
 16. A method according to claim15 wherein the binder also does not bind to [Leu]enkephalin. SEQ ID No:4.
 17. A method according to claim 15 , wherein said Pro-Enkephalin orfragment thereof is SEQ ID No. 1, and optionally one or more of SEQ IDNo. 2, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 9, SEQ IDNo. 10 or SEQ ID No.
 11. 18. A method according to claim 15, whereinsaid threshold level of Pro-Enkephalin or fragments thereof is 80pmol/L.
 19. A method according to claim 15, wherein the binder is usedin an assay for determining the level of Pro-Enkephalin or fragmentsthereof and the sensitivity of said assay is able to quantify thePro-Enkephalin or Pro-Enkephalin fragments of healthy subjects and is<15pmol/L.
 20. A method according to claim 15, wherein said bodily fluid isblood, serum, plasma, urine, cerebro spinal liquid (csf) or saliva. 21.A method according to claim 15, wherein said determination ofPro-Enkephalin or fragments thereof is performed more than once in onesubject.
 22. A method according to claim 15, wherein said monitoring isperformed in order to evaluate the response of said subject topreventive and/or therapeutic measures taken.
 23. A method according toclaim 15, performed in order to stratify said subjects into risk groups.24. A method according to claim 15, wherein said level of Pro-Enkephalinor fragments thereof are correlated with a risk of death or an adverseevent in a subject, wherein an elevated level above a certain thresholdis predictive for an enhanced risk of death or adverse events andwherein said subject is male.
 25. A point-of-care device for performingassays near a subject, wherein said point-of-care device is capable ofperforming a method of claim 15 and comprises an antibody or antibodyfragment that does not bind to enkephalin peptides [Met]enkephalin SEQID No:
 3. 26. A kit which comprises: a) a point-of-care device forperforming assays near a subject, capable of performing a method ofclaim 15 and b) an antibody or antibody fragment that does not bind toenkephalin peptides [Met]enkephalin SEQ ID No:
 3. 27. A method for (a)diagnosing or monitoring kidney function in subject or (b) diagnosingkidney dysfunction in a subject or (c) predicting or monitoring the riskof an adverse events in a subject wherein said adverse event is selectedfrom the group comprising worsening of kidney dysfunction includingkidney failure, loss of kidney function and end-stage kidney disease ordeath due to kidney dysfunction including kidney failure, loss of kidneyfunction and end-stage kidney disease or (d) predicting or monitoringthe success of a therapy or intervention comprising determining thelevel of Pro-Enkephalin or fragments thereof in a bodily fluid obtainedfrom said subject and determining at least one additional clinicalparameter that is age, BUN, NGAL, Creatinine Clearance, Creatinine orApache Score and (a) correlating said level of Pro-Enkephalin orfragments thereof and at least one additional clinical parameter withkidney function in a subject, or (b) correlating said level ofPro-Enkephalin or fragments thereof at least one additional clinicalparameter with kidney dysfunction, wherein an elevated level above acertain threshold is predictive or diagnostic for kidney dysfunction insaid subject, or (c) correlating said level of Pro-Enkephalin orfragments thereof at least one additional clinical parameter with saidrisk of an adverse event in a subject with kidney disease, wherein anelevated level above a certain threshold is predictive for an enhancedrisk of said adverse events, or (d) correlating said level ofPro-Enkephalin or fragments thereof at least one additional clinicalparameter with success of a therapy or intervention in a subject withkidney disease, wherein a level below a certain threshold is predictivefor a success of therapy or intervention, wherein said Pro-Enkephalin orfragment thereof is one or more of SEQ ID No. 1, SEQ ID No. 2, SEQ IDNo. 5, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10 or SEQ IDNo. 11, wherein the level of Pro-Enkephalin or fragments thereof of isdetermined by using an assay with at least one binder to Pro-Enkephalinor fragments thereof that does not bind to SEQ ID No.: 3, and whereinthe sensitivity of the assay is able to quantify the Pro-Enkephalin orPro-Enkephalin fragments of healthy subjects and is<15 pmol/L.
 28. Amethod according to claim 27, wherein said Pro-Enkephalin or fragmentthereof is SEQ ID No. 1, and optionally one or more of SEQ ID No. 2, SEQID No. 5, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10 or SEQID No.
 11. 29. A method according to claim 27, wherein said binders donot bind to [Leu]enkephalin. SEQ ID No:
 4. 30. A method according toclaim 27, wherein said binders bind to SEQ ID No.
 6. 31. A methodaccording to claim 27, wherein said binders bind to a region within anamino acid sequence selected from the group consisting of SEQ ID No. 1,2, 5, 6, 7, 8, 9 and
 10. 32. A method according to claim 27, whereinsaid binders bind to a region within an amino acid sequence selectedfrom the group consisting of SEQ ID No. 2, 5, 6, and
 10. 33. A methodaccording to claim 27, wherein said threshold level of Pro-Enkephalin orfragments thereof is 80 pmol/L.
 34. A method according to claim 27,wherein the level of Pro-Enkephalin or fragments thereof is measuredwith an immunoassay and said binder is an antibody or an antibodyfragment or a non-Ig-Scaffold binding to Pro-Enkephalin or fragmentsthereof.
 35. A method according to claim 27, wherein said bodily fluidis blood, serum, plasma, urine, cerebro spinal liquid (csf) or saliva.36. A method according to claim 27, wherein said determination ofPro-Enkephalin or fragments thereof of is performed more than once inone subject.
 37. A method according to claim 27, wherein said monitoringis performed in order to evaluate the response of said subject topreventive and/or therapeutic measures taken.
 38. A method according toclaim 27, wherein said monitoring is performed in order to stratify saidsubjects into risk groups.
 39. A point-of-care device for performingassays near a subject, wherein said point-of-care device comprises anassay capable of performing a method of claim 27 with sensitivity ableto quantify the Pro-Enkephalin or Pro-Enkephalin fragments of healthysubjects and is<15 pmol/L.
 40. A kit which comprises: a point-of-caredevice capable of performing a method of claim 27 near a subject whichcomprises an assay for determining the level of Pro-Enkephalin orfragments thereof, wherein the sensitivity of the assay is able toquantify the Pro-Enkephalin or Pro-Enkephalin fragments of healthysubjects and is<15 pmol/L.
 41. A method for diagnosing or monitoringkidney function using a kit or assay to detect Pro-Enkephalin orfragments thereof in a subject, wherein said kit or assay comprises atleast one antibody capable of binding Pro-Enkephalin or fragmentsthereof in a sample of bodily fluid obtained from said subject whichdoes not bind to enkephalin peptides [Met]enkephalin SEQ ID No: 3, saidmethod comprising: determining the level of Pro-Enkephalin or fragmentsthereof of in a sample of bodily fluid obtained from a subject using akit or assay comprising an antibody that binds to Pro-Enkephalin orfragments thereof which does not bind to enkephalin peptides[Met]enkephalin SEQ ID No: 3, and additionally using an assay fordetermining the level of at least one additional clinical parameter thatis BUN, NGAL, Creatinine Clearance, Creatinine or Apache Score andcorrelating said level of Pro-Enkephalin or fragments thereof and atleast one additional clinical parameter with kidney function in asubject, or kidney dysfunction wherein an elevated level above a certainthreshold is predictive or diagnostic for kidney dysfunction in saidsubject, or risk of an adverse event in a subject with kidney disease,wherein an elevated level above a certain threshold is predictive for anenhanced risk of said adverse event, or success of a therapy orintervention in a subject with kidney disease, wherein saidPro-Enkephalin or fragment thereof is SEQ ID No. 1, and optionally oneor more of SEQ ID No. 2, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 8, SEQID No. 9, SEQ ID No. 10 or SEQ ID No.
 11. 42. A method according toclaim 41, wherein the antibody of said kit or assay capable of bindingPro-Enkephalin or fragments thereof does not bind to [Leu]enkephalin.SEQ ID No:
 4. 43. A method according to claim 41, wherein the antibodyof said kit or assay capable of binding Pro-Enkephalin or fragmentsthereof binds to a region within an amino acid sequence selected fromthe group consisting of SEQ ID No. 1, 2, 5, 6, 7, 8, 9 and
 10. 44. Amethod according to claim 41, wherein the sensitivity of the assay usedfor determining the level of Pro-Enkephalin or fragments thereof is ableto quantify the Pro-Enkephalin or Pro-Enkephalin fragments of healthysubjects and is<15 pmol/L.
 45. A method according to claim 41, whereinsaid threshold level of Pro-Enkephalin or fragments thereof of is 80pmol/L.
 46. A method according to claim 41, wherein said bodily fluid isblood, serum, plasma, urine, cerebro spinal liquid (csf) or saliva. 47.A method according to claim 41, wherein said monitoring is performed inorder to evaluate the response of said subject to preventive and/ortherapeutic measures taken.
 48. A method according to claim 41, whereinsaid level of Pro-Enkephalin or fragments thereof are correlated with arisk of death or an adverse event in a subject, wherein an elevatedlevel above a certain threshold is predictive for an enhanced risk ofdeath or adverse events and wherein said subject is male.
 49. A methodof using a kit or assay to detect Pro-Enkephalin or fragments thereof ina subject, wherein said Pro-Enkephalin or fragment is one or more of SEQID No. 1, SEQ ID No. 2, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 8, SEQ IDNo. 9, SEQ ID No. 10 or SEQ ID No. 11, and wherein said kit or assaycomprises at least one antibody capable of binding Pro-Enkephalin orfragments thereof in a sample of bodily fluid obtained from saidsubject, which does not bind to enkephalin peptides [Met]enkephalin SEQID No: 3, said method comprising: determining the level ofPro-Enkephalin or fragments thereof in a sample of bodily fluid obtainedfrom a subject using at least one antibody within said kit or assay thatbinds to Pro-Enkephalin or fragments thereof which does not bind toenkephalin peptides [Met]enkephalin SEQ ID No: 3, wherein a level ofPro-Enkephalin or fragments thereof below 80 pmol/L is predictive for asuccess of therapy or intervention or, a level of Pro-Enkephalin orfragments thereof above 80 pmol/L is correlated with a risk of death oran adverse event in a subject or a level of Pro-Enkephalin or fragmentsthereof above 80 pmol/L is predictive or diagnostic for kidneydysfunction in said subject.
 50. A method according to claim 49, whereinsaid bodily fluid is blood, serum, plasma, urine, cerebro spinal liquid(csf) or saliva.